Fundraising FoxInnovate Biopharmaceuticals
Raleigh, US · Founded 2014 · Delaware corporation · 1 known investors
Find your way into Innovate Biopharmaceuticals
Sign up to see every warm intro you have to Innovate Biopharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Innovate Biopharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
KW
Kendyle WoodardExecutive
MR
Michael RiddlingExecutive
JT
Jawahar TandonExecutive
JM
Jay MadanNamed on SEC filing
SL
Sandeep LaumasNamed on SEC filing
CP
Christopher P. PriorNamed on SEC filing
Board
SR
Saira RamasastryBoard director
RP
Roy ProujanskyBoard director
AM
Anthony MaidaBoard director
LJ
Lorin JohnsonBoard director
VT
Vivek TandonBoard director
DT
Devinder TandonBoard director
Investors · 1
OrbiMedreportedNew York · $1M – $75M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$191.3M disclosed across 16 rounds · 2014–2020
▶$22.6MraisedMay 2020 · 149 investors · PharmaceuticalsRule 506(b)
▶$22.6MraisedMay 2020 · 149 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roy ProujanskyDirector
- Edward J. SitarExecutive Officer
- Sandeep LaumasDirector
- Lorin K. JohnsonDirector
- Nissim DarvishDirector
- Mark SirgoDirector
- John TemperatoExecutive Officer, Director
- Offering amount
- $22.6M
- Amount sold
- $22.6M
- Sales commissions
- $2.1M
- Placement agents
- Wynston Hill Capital, Westpark Capital, Inc., GP Numenkari Inc., National Securities Corporation, William Blair & Company, LLC.
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedJan 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedJan 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sandeep LaumasExecutive Officer, Director
- Jay MadanExecutive Officer, Director
- Anthony MaidaDirector
- Edward J SitarExecutive Officer
- Saira RamasastryDirector
- Roy ProujanskyDirector
- Lorin JohnsonDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$487.1KraisedMay 2019 · 17 investors · PharmaceuticalsRule 506(b)
▶$487.1KraisedMay 2019 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jay P MadanExecutive Officer, Director
- Sandeep LaumasExecutive Officer, Director
- Lorin K JohnsonDirector
- Saira RamasastryDirector
- Roy ProujanskyDirector
- Anthony E Maida IIIDirector
- Offering amount
- $487.1K
- Amount sold
- $487.1K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.7MraisedMay 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$8.7MraisedMay 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sandeep LaumasExecutive Officer, Director
- Jay MadanExecutive Officer, Director
- Roy ProujanskyDirector
- Lorin JohnsonDirector
- Saira RamasastryDirector
- Anthony MaidaDirector
- Offering amount
- $8.7M
- Amount sold
- $8.7M
- Sales commissions
- $612.1K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.7MraisedApr 2019 · 17 investors · PharmaceuticalsRule 506(b)
▶$9.7MraisedApr 2019 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Saira RamasastryDirector
- Roy ProujanskyDirector
- Anthony MaidaDirector
- Jay MadanExecutive Officer, Director
- Sandeep LaumasExecutive Officer, Director
- Lorin JohnsonDirector
- Offering amount
- $9.7M
- Amount sold
- $9.7M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedMar 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$5.5MraisedMar 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roy ProujanskyDirector
- Jay MadanExecutive Officer, Director
- Lorin JohnsonDirector
- Sandeep LaumasExecutive Officer, Director
- Anthony MaidaDirector
- Saira RamasastryDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedOct 2018 · 1 investors · BiotechnologyRule 506(b)
▶$5.2MraisedOct 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Saira RamasastryDirector
- Roy ProujanskyDirector
- Anthony MaidaDirector
- Christopher PriorExecutive Officer, Director
- Lorin JohnsonDirector
- Jay MadanExecutive Officer, Director
- Sandeep LaumasExecutive Officer, Director
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedFeb 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedFeb 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jay MadanExecutive Officer, Director
- Sandeep LaumasExecutive Officer, Director
- Christopher PriorExecutive Officer
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Innovate Biopharmaceuticals's investors?
- Innovate Biopharmaceuticals's investors include OrbiMed.
- How much funding has Innovate Biopharmaceuticals raised?
- Innovate Biopharmaceuticals has disclosed $191.3M raised across 16 rounds.
- Where is Innovate Biopharmaceuticals headquartered?
- Innovate Biopharmaceuticals is headquartered in Raleigh, US.